Elypta announces initiation of the pivotal AURORAX-087A study

Elypta has initiated preparations for the AURORAX-087 study to generate evidence to support regulatory approval for the first application, monitoring of recurrence in renal cell carcinoma patients. The study is the largest so far centered around kidney cancer diagnostics. Factory-CRO, a CRO specialised in clinical trial management in medtech and IVD was recently selected for the managment of the study.

First Word Medtech covered the announcement here:

http://www.firstwordmedtech.com/node/1022323

Karl Bergman